Sarepta needs to raise money. Who cares? At its current valuation, Sarepta is a great, speculative biotech story. Selling stock to raise much-needed money doesn't make Sarepta any less interesting. In fact, an offering may actually spur more investors to take a look at the stock. Having more money on hand will definitely help Sarepta if the management decides it wants to partner eteplirsen.
Eteplirsen has the potential to treat about 15% of the 12,000 DMD patients in the U.S. Let's do some simple math: 1,800 patients times $300,000 (a guesstimate of eteplirsen's cost but certainly not outrageous for a therapy serving a rare, genetic disease) yields a potential treatment market valued at $540 million. That's just the U.S., I'm not including Europe or the rest of the world.
The 48-week eteplirsen data are expected in October.
Paul A. emails, "I read your tweet where you said the Biocryst Pharmaceuticals (BCRX) results from its gout drug sucked. I don't understand why you feel this way because everything seems very positive to me. Care to explain?"BioCryst's ulodesine (BCX4208) may compare favorably against placebo in its own phase II studies, but the drug's efficacy and safety profile is weaker than Ardea BioSciences' competing gout drug lesinurad, which is already well into phase III studies. AstraZeneca bought Ardea for $1.23 billion last April. BioCryst needs to find a partner for ulodesine but who will want to acquire or license a gout drug that is behind and inferior to a competitor? Lastly, a voice from the choir of stupid. What's funny about the following email is that it was sent Thursday night, after the Amarin approval, which I predicted correctly. In fact, I went a perfect 5-0 in my Summer FDA Drug Approval Contest. Bernard A. writes: "Dear bald head -- I have never seen anybody in my entire life who makes more bad calls on stock approval than you. Aren't you the same moron who know somebody who can guess the outcome of the advisory committee, aren't you the one who guess Arna will not get approved, or maybe you are the one who talked an investor a few weeks ago she told you Amrn will not get approved. You are a moron!!" Thanks for sharing, Bernie. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV